Skip to main content

Table 1 Characteristics of 2010 incident U.S. hemodialysis patients, by vascular access at dialysis start and systemic lupus erythematosus status

From: Comparison of vascular access outcomes in patients with end-stage renal disease attributed to systemic lupus erythematosus vs. other causes: a retrospective cohort study

Characteristic Overall Vascular Access on First Dialysis:
Any   Catheter only   AVF/AVG in place   AVF/AVG used  
Attributed Cause of ESRD:
SLE Other SLE Other SLE Other SLE Other
N (%) 67,748 (100 %) 517 (0.8 %) 66,961 (99.2 %) 384 (0.9 %) 40,527 (99.1 %) 85 (0.6 %) 13,409 (99.4 %) 48 (0.4 %) 13,025 (99.6 %)
Demographic          
Mean (SD) age, years 64.1 (14.9) 40.3 (15.3)a 64.3 (14.8)a 39.0 (15.0)a 64.1 (15.3)a 41.7 (15.8)a 63.8 (14.3)a 48.6 (14.2)a 65.4 (13.6)a
Female, n (%) 29,276 (43.4 %) 410 (79.3 %)a 28,866 (43.1 %)a 315 (82.0 %)a 17,951 (44.3 %)a 64 (75.3 %)a 5,675 (42.3 %)a 31 (64.6 %)b 7,785 (59.8 %)b
Race/ethnicity, %          
 Non-Hispanic white 34,731 (51.5 %) 129 (25.0 %)a 34,602 (51.7 %)a 89 (23.2 %)a 20,813 (51.4 %) a 22 (25.9 %)a 6,644 (49.6 %)a 18 (37.5 %) 7,145 (54.9 %)
 Black 20,221 (30.0 %) 284 (54.9 %)a 19,937 (29.8 %)a 221 (57.6 %)a 11,984 (29.6 %)a 42 (49.4 %)a 4,108 (30.6 %)a 21 (43.8 %) 3,845 (29.5 %)
 Hispanic white 8,722 (12.9 %) 72 (13.9 %)a 8,650 (12.9 %)a 56 (14.6 %)a 5,526 (13.6 %)a 10 (11.8 %)a 1,829 (13.6 %)a c 1,295 (9.9 %)
 Other 3,804 (5.6 %) 32 (6.2 %)a 3,772 (5.6 %)a 18 (4.7 %)a 2,204 (5.4 %)a 11 (12.9 %)a 828 (6.2 %)a c 740 (5.7 %)
Insurance at dialysis start, %          
 Private 16,546 (24.5 %) 137 (26.5 %)a 16,409 (24.5 %)a 93 (24.2 %)a 9,441 (23.3 %)a 25 (29.4 %)b 3,387 (25.3 %)b 19 (39.6 %) 3,264 (25.1 %)
 Medicare/other 27,159 (40.3 %) 104 (20.1 %)a 27,055 (40.4 %)a 67 (17.5 %)a 16,037 (39.6 %)a 21 (24.7 %)b 5,315 (39.6 %)b 16 (33.3 %) 3,581 (27.5 %)
 Medicaid 18,183 (27.0 %) 201 (38.9 %)a 17.982 (26.9 %)a 160 (41.7 %)a 10,897 (26.9 %)a 32 (37.7 %)b 3,821 (28.5 %)b c 5,703 (43.8 %)
 None 5,590 (8.3 %) 75 (14.5 %)a 5,515 (8.2 %)a 64 (16.7 %)a 4,152 (10.3 %)a c 886 (6.6 %)b c 477 (3.7 %)
Clinical          
Pre-ESRD nephrology care, % 38,937 (65.7 %) 307 (67.0 %) 38,630 (65.7 %) 200 (60.2 %)b 18,042 (52.4 %)b 64 (81.0 %) 9,034 (74.4 %) 43 (91.5 %) 11,554 (94.3 %)
Mean (SD) BMI, kg/m2 29.5 (7.9) 27.3 (7.5)a 29.5 (7.9)a 27.2 (7.5)a 29.3 (8.0)a 27.7 (6.9)a 29.9 (7.9)a 27.3 (8.3)b 29.8 (7.7)b
Congestive heart failure, % 22,893 (33.9 %) 85 (16.4 %)a 22,808 (34.1 %)a 59 (15.4 %)a 14,292 (35.3 %)a 18 (21.2 %)b 4,819 (35.9 %)b c 3,697 (28.4 %)
Diabetes, % 38,918 (57.7 %) 62 (12.0 %)a 38,856 (58.0 %)a 44 (11.5 %)a 22,940 (56.6 %)a 12 (14.1 %)a 8,401 (62.7 %)a c 7,515 (57.7 %)a
Peripheral vascular disease, % 9,569 (14.2 %) 21 (4.1 %)a 9,548 (14.3 %)a 16 (4.2 %)a 5,494 (13.6 %)a c 2,267 (16.9 %)b c 1,787 (13.7 %)b
Smoking, % 4,369 (6.5 %) 26 (5.0 %) 4,343 (6.5 %) 13 (3.4 %)b 2,645 (6.5 %)b 10 (11.8 %) 889 (6.6 %) c 810 (6.2 %)
Transplanted within 1 year, % 853 (1.3 %) 13 (2.5 %)b 840 (1.3 %)b c 429 (1.1 %)b c 160 (1.2 %) c 252 (1.9 %)
Recovered renal function within 1 year, % 1048 (1.6 %) 13 (2.5 %) 1035 (1.6 %) 11 (2.9 %) 909 (2.2 %) c 85 (0.6 %) c 41 (0.3 %)
  1. AVF arteriovenous fistula, AVG arteriovenous graft, ESRD end-stage renal disease, SLE systemic lupus eythematosus
  2. aP <0.001 and bP < 0.05 for SLE vs. other ESRD, by t or chi-square/Fisher’s exact test, as appropriate
  3. cNot reportable due to cell size < 10